Cardio Diagnostics Holdings, Inc. (CDIO)
NASDAQ: CDIO · Real-Time Price · USD
0.467
+0.028 (6.29%)
At close: Feb 4, 2025, 4:00 PM
0.483
+0.016 (3.51%)
Pre-market: Feb 5, 2025, 5:52 AM EST
Company Description
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease.
It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease.
Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.
Cardio Diagnostics Holdings, Inc.
| Country | United States |
| Founded | 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Meeshanthini Dogan |
Contact Details
Address: 311 West Superior Street, Suite 444 Chicago, Illinois 60654 United States | |
| Phone | 302 281 2147 |
| Website | cardiodiagnosticsinc.com |
Stock Details
| Ticker Symbol | CDIO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001870144 |
| CUSIP Number | 14159C103 |
| ISIN Number | US14159C1036 |
| Employer ID | 87-0925574 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Dr. Meeshanthini V. Dogan Ph.D. | Co-Founder, Chief Executive Officer and Director |
| Elisa Michael Luqman Esq., J.D., M.B.A. | Chief Financial Officer |
| Dr. Robert A. Philibert M.D., Ph.D. | Co-Founder, Chief Medical Officer and Director |
| Timur Dogan Ph.D. | Chief Technology Officer |
| Khullani Abdullahi J.D. | Vice President of Revenue and Strategy |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 4, 2024 | 8-K | Current Report |
| Dec 3, 2024 | EFFECT | Notice of Effectiveness |
| Dec 3, 2024 | 424B3 | Prospectus |
| Nov 26, 2024 | UPLOAD | Filing |
| Nov 22, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Nov 18, 2024 | 8-K | Current Report |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Oct 4, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Oct 4, 2024 | DEF 14A | Other definitive proxy statements |
| Sep 25, 2024 | ARS | Filing |